# A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone

> **NCT04158947** · PHASE2 · UNKNOWN · sponsor: **xuexin he** · enrollment: 130 (estimated)

## Conditions studied

- HER2-positive Breast Cancer
- Brain Metastases

## Interventions

- **DRUG:** Afatinib
- **DRUG:** T-DM1

## Key facts

- **NCT ID:** NCT04158947
- **Lead sponsor:** xuexin he
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-10
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-03-31
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2020-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158947, "A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04158947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*